BTIG Initiates Coverage On AC Immune with Buy Rating, Announces Price Target of $8
Portfolio Pulse from Benzinga Newsdesk
BTIG has initiated coverage on AC Immune (NASDAQ:ACIU) with a Buy rating and set a price target of $8.
May 31, 2024 | 9:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG has initiated coverage on AC Immune with a Buy rating and set a price target of $8, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $8 by BTIG is likely to boost investor confidence and attract new investments, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100